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Bone reconstruction in the maxillofacial region is a challenging task due to the exclusive anatomical complexity of the tissue, aesthetic 
requirements and functional demands. The gold standard method for maxillofacial reconstruction is based on autogenous bone grafting, 
which is associated with certain drawbacks. In this review, we describe recent bone tissue engineering approaches in reconstructive surgery of 
the maxillofacial region. Proper cell sources, scaffolds, signaling molecules as well as recent bioreactor technology are discussed.   
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Introduction 
The maxillofacial region, consisting of bone, cartilage, soft tissue, 
nerves, and blood vessels, is a relatively complex tissue. Critical-
size segmental bone defects in this region occur as a result of 
cancer resection, trauma, congenital malformations and 
progressive skeletal deformity. Reconstruction of maxillofacial 
bones is complex due to unique aesthetic requirements and 
functional demands, which include mastication and expression 
of emotions.  Bone defects in the craniomaxillofacial skeleton 
have complex three-dimensional (3D) structural characteristics 
(Figure 1), which make their restoration difficult to achieve. 
Resection of a tumor mass in the mandible has a marked impact 
on facial appearance, function and general welfare of patients. 
Facial bone defects and their associated complex neurovascular 
structures in the region present a major challenge to achieve a 
satisfactory reconstruction.  
Several methods have been used for bone reconstruction in 
the maxillofacial region, which include autogenous bone grafts, 
allografts, alloplasts and xenografts (1). Autogenous bone grafts 
are considered the gold standard to which other materials are 
compared. However, autogenous bone grafts are associated with 
certain disadvantages such as limited availability for the 
reconstruction of large defects, difficulty obtaining the required 
shape and donor site morbidity (2). Autogenous bone graft 
induces osteoconduction, osteoinduction and osteogenesis. 
Osteoconduction occurs when the bone graft material acts as a 
template for new bone growth perpetuated by the native bone 
(3). Osteoinduction involves stimulating osteoprogenitor cells to 
differentiate to osteoblasts, which then begin new bone 
formation. The most widely studied osteoinductive cell 
mediators are bone morphogenetic proteins (BMPs), which can 
be found in large concentrations in cortical bone (4). 
Osteogenesis occurs when vital osteoblasts originating from the 
bone graft material contribute to new bone growth. Although 
autologous bone grafts have long been considered the gold 
standard treatment for large segmental bone defects, there are 
three major limitations with the use of an autogenous free bone 
graft namely poor osseointegration and excessive resorption 
when the defect is larger than 6 to 9 cm3, insufficient blood 
supply to the graft and the surrounding tissues due to irradiation 
scarring and infection, and donor site morbidity (5). 
Specifically, autogenous bone grafts and bone marrow 
components have been used for facial bone reconstruction. 
However, they have drawbacks such as limited availability and 
the reported morbidity associated with harvesting of bone grafts. 
Biomaterials, despite their availability, have a high failure rate 
due to poor vascularity, limited mechanical properties and 
deficiency in complete osseointegration with the surrounding 
native bone.  These limitations have inspired a search for 
innovative techniques for bone bioengineering and developing 
more reliable biomaterials. Alternative options include bone 
allografts from cadavers, which are also associated with some 
disadvantages (6). 
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Figure 1. (A) A residual continuity defect following the resection of a 
mandibular tumor for reconstruction; (B) The shape of the resected 
segment that requires replacement. 
Tissue engineering approaches that deliver osteoconductive 
scaffolds, osteoprogenitor cells and growth factors directly into 
the bone defects hold great potential for achieving optimal bone 
healing in difficult cases while eliminating the drawbacks 
associated with the conventional treatments. Tissue engineering 
approaches provide powerful tools to achieve long-term 
satisfactory results enabling customized reconstruction with the 
support of natural healing processes. Undoubtedly, further 
advances in tissue engineering are essential to achieve reliable 
and satisfactory clinical results (7).  
Herein, we highlight the recent advances in tissue 
engineering in an attempt to overcome the clinical challenges in 
reconstructive surgery of the maxillofacial region.  
Stem cells in maxillofacial bone tissue engineering 
The cells are among the key components of bone tissue 
engineering. Proper cell sources for bone regeneration are either 
differentiated bone cells or pluri/multi potent cells holding the 
capacity of osteogenic differentiation (8, 9) (Figure 2).  
Adult mesenchymal stem cells (MSCs) possess the capacity of 
self-renewal and the potential for multi-lineage differentiation; 
therefore, they serve as a suitable source of stem cells for bone 
tissue engineering. These cells can be isolated from the bone 
marrow, adipose tissue, umbilical cord blood, dental pulp, etc.; 
MSCs from these sources have different characteristics and 
diverse proliferation and differentiation capacities (8, 10). 
Although clinical applications might be based on their 
differentiation capacity, it is more dependent on their 
abundance, frequency, and expansion potential (11). Moreover, 
MSCs are proven to be immuno-privileged cells (12). They may 
be available for cell replacement therapy in HLA-incompatible 
hosts before and after osteogenic differentiation in vitro. Several 
studies have shown adequate engraftment of MSCs after their 
allogeneic and even xenogenic transplantation in vivo (13). It is 
well-known that MSCs are capable of forming at least 3 cell 
lineages: osteogenic, chondrogenic and adipogenic. Other 
lineages such as myogenic, neurogenic and tenogenic may be 
derived from MSCs as well.  
Bone marrow derived mesenchymal stem cells (BMSCs), 
which are also known as bone marrow derived stromal cells, are 
the most well-known source of MSCs for use in bone tissue 
engineering, which can be easily isolated from the iliac crest 
aspirates, core biopsies and surgical waste (14). Lee et al., 
reported successful reconstruction of a 15 cm segmental 
mandibular defect with BMSCs. In their human trial, a central 
hemangioma was diagnosed in a 14-year-old male patient. The 
resected jaw was freeze-dried to 7.6 × 10-6 mmHg for 48 hours 
and was then perforated using surgical burs. Autogenous BMSCs 
were aspirated, isolated and cultured in vitro. They were 
repositioned in the mandibular defect area. One year post-
operatively, the mandible demonstrated excellent clinical and 
radiographic evidence of bone regeneration (15). 
Interestingly, researchers have found a difference between 
MSCs from long bones and MSCs from the mandible. Human 
mandibular or maxillary bone marrow stromal cells demonstrate 
greater cell proliferation, delayed senescence and stronger 
expression of osteoblastic markers compared to iliac crest-
derived marrow cells from the same patients (16). This suggests 
distinct functions, differentiation potential and osteogenic 
potential of mandibular vs. long-bone marrow stromal cells. 
Culture of MSCs of the mandible form more colonies, suggesting 
a larger colony forming unit (CFU) population (17). 
Adipose tissue (AT) is known as one of the richest sources of 
MSCs (18). Although there is evidence that AT-MSCs are not 
able to support formation of hematopoietic marrow, they are 
accepted as a promising source of stem cells in bone tissue 
engineering, since they have proven to have the capacity of 
osteogenic differentiation (19, 20). In addition, given the well-
documented ability to yield larger numbers of MSCs under local 
anesthesia, AT may provide a more efficient source of MSCs for 
research and clinical applications with decreased patient 
morbidity during cell harvesting (21). Therefore, AT-MSCs 
could be a good resource and an alternative to BMSCs. Cowan et 
al., showed that their harvesting technique usually yields ∼800 
mg of subcutaneous fat tissue and 0.6 mg bone marrow per 
mouse and therefore, the yield of cells is much higher from fat 
than from bone marrow. They also described that the 
proliferation rate of AT-MSCs was substantially higher than that 
of BMSCs during subsequent in vitro expansion. Because AT-
MSCs proliferate rapidly in culture, populations can readily 
reach the high levels needed for clinical application (22). 
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Figure 2. Cell sources for bone tissue engineering 
Recent clinical studies have focused on the use of human AT-
MSCs (23). The cells were utilized to replace the lost bone in 
critical-size calvarial defects in a rat model (24). Some clinical 
reports focusing on AT-MSCs in the reconstruction of the 
cranium, maxilla and mandible showed variable rates of 
success (25). To date, there is a paucity of data defining the 
mechanisms through which AT-MSCs influence an osseous 
defect. Whether or not AT-MSCs directly form bone or 
function as efficient ‘factories’ to produce potent pro-
osteogenic cytokines remains unknown. The reconstruction 
of large mandibular defects after tumor resection using AT-
MSCs, BMP-2, and β-tricalcium phosphate (β-TCP) scaffold 
combined with computer-aided manufacturing technique has 
been reported (26). Three patients with recurrent 
ameloblastomas requiring segmental mandibular resection 
were included in a study. The reconstructions of the three 
mandibular defects were successful in bridging the large 
defects averaging 8.2 cm. Also, the authors reported 
successful use of AT-MSCs tissue engineered construct to 
treat a large anterior mandibular defect (27).  
Scaffolds and biomaterials in maxillofacial bone tissue 
engineering 
In critical size bone defects, one of the major considerations is 
to bridge the physical gap. Scaffolds, as a porous structure, 
should ideally mimic the extracellular environment to 
encourage cells to attach, migrate, proliferate, differentiate  
Figure 3. Biomaterials and scaffolds for bone tissue engineering 
and finally to be replaced with the natural tissue including cells 
and extracellular matrix (28). Although there are a number of 
scaffold-free-cell-based therapies, without scaffolding it is hard 
to imagine that cells could assume aggregate function, induce 
vascularization, and build a higher-order 3D structure (29). 
Scaffolds have three features namely material, architecture 
(micro/macro structure) and surface properties (Figure 3). 
Bone is known as a mineralized tissue containing high 
amount of calcium phosphate. Therefore, not surprisingly, the 
initial bone substitute materials were ceramic materials. 
Although in the past bone substitute materials were designed to 
be bio-inert, later the paradigm shifted towards the design of 
bioactive materials that integrated with biological cytokines and 
cells and regenerated tissues (30). Ideally, biomaterials for bone 
tissue engineering applications should be both osteoinductive 
and osteoconductive with the capacity of osseointegration (31). 
Therefore, these materials should rather encourage the 
differentiation of progenitor cells to osteoblastic lineage, support 
bone growth, stimulate the in-growth of the surrounding bone 
and finally, be able to integrate into the neighboring bone tissue. 
Materials for bone scaffolding can be generally categorized into 
bioactive inorganic materials, polymers and composites. 
Most ceramics used for the reconstruction of oral and 
maxillofacial region are either preformed blocks, granules of 
porous hydroxyapatite (HA), TCP or setting cement 
commonly called biphasic calcium phosphate (BCP). These 
brittle materials have limited tensile strength (32).  
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Figure 4. (A) Alveolar cleft; (B) Injection of rh-BMP-7 (Op-1) at the bony defect; (C) Adaptation of Op-1 to fill the defect before closure of the 
mucoperiosteal flap; (D) Immediate post-operative occlusal radiograph showing an alveolar cleft; (E) Three-month post-operative occlusal 
radiograph of the same case showing bone formation and eruption of the associated tooth 
 
Bioactive glass is a combination of a silica-based material 
with a biocompatible material such as calcium phosphate, 
forming a bond between an implant and host tissue. This 
material has been used as a filler of bone cavities in the cranio-
maxillofacial region ,i.e. frontal sinus obliteration. However, it 
is not suitable for the reconstruction of continuity defects of 
the jawbone due to the lack of mechanical properties (33). 
Porous polyethylene has been used for the reconstruction of 
cranio-maxillofacial defects. This material is a dense porous 
polyethylene with a pore size of 100 to 250 μm. Bioresorbable 
plates and screws made of polylactic acid have been 
successfully used for paediatric craniofacial reconstructive 
procedures including the release of craniosynostoses and 
reconstruction of cranial defects (34). 
Signalling for osteogenesis and bone remodelling  
In bone tissue engineering, it is necessary to provide the 
physical and chemical environments required to induce bone 
remodelling. Bioactive molecules, mechanical loads and 
electromagnetic fields are famous stimuli for bone healing and 
remodelling since they trigger several molecular cascades in 
cells and the surrounding tissues.  
Specifically, bioactive molecules including BMPs and 
transforming growth factor beta (TGF-β) are responsible for 
osteogenic differentiation and acceleration of extra-cellular 
matrix production and consequently tissue integration (35). 
The BMPs can attract mesenchymal progenitor cells and act as 
chemotactic mitogenic and differentiating agents to induce 
chondrogenic and osteogenic differentiation. This fact implies 
that BMPs are essential signaling molecules for 
intramembranous and endochondral bone formation. In 
maxillofacial reconstruction, BMP-2 and BMP-7 have been 
principally studied for clinical applications and use in 
combination with collagen/collagen composite scaffolds (36). 
To date, reconstruction of 4 to 8 cm mandibular defects and 
cleft alveolus as well as maxillary sinus augmentation have been 
successfully performed using BMP-2 or BMP-7 combined with 
collagen scaffolds (37). In 2001, US Food and Drug 
Administration (FDA) approved the application of BMPs for 
sinus augmentation and alveolar ridge augmentation associated 
with extraction sockets. The BMP-2 and 7 are now 
commercially available for clinical use. Recently, Ayoub et al., 
demonstrated the successful clinical application of rhBMP-7 
(Op-1) for reconstruction of alveolar cleft (Figure 4). This is the 
first application of this cytokine for the reconstruction of 
critical-size defects in the maxillofacial region (38).  
It has been well demonstrated that bone cells respond to 
mechanical loads both in vivo and in vitro. In bone tissue 
engineering, it is promising to take advantage of such 
mechanical responses to stimulate matrix production and 
induce osteogenic differentiation (39). Also, cells can sense 
mechanical properties of the scaffold or surface and react. 
Surfaces with higher stiffness or Young’s modulus can 
encourage mesenchymal stem cells to differentiate to bone 
lineage. It has been demonstrated that mechanical stress 
increases alkaline phosphatase activity, a marker of osteoblast 
differentiation, increases the expression of osteocalcin, which is 
an osteoblast-specific extracellular matrix (ECM) protein, 
induces runt-related transcription factor 2 (Runx2) activation 
and increases the expression of osterix in osteoblast-like 
MC3T3-E1 cells (40). Ultrasound is a method to generate 
mechanical stimulation for clinical application. Ultrasound 
treatments are successfully used for acceleration of 
osseointegration of metal biomaterials in osteoporotic patients. 
Moreover, these treatments have shown to diminish the healing 
period of fresh fractures of the extremities by up to 38%, and to 
heal delayed and non-unions by up to 90% and 83%, 
respectively (41). This implies that mechanical stimulation has 
a promising future in oral and maxillofacial surgery.  
Although electrical stimulation (ES) is effective in 
rehabilitation of nerve and muscle tissues, it has been 
successfully applied clinically to stimulate osteogenesis in bone 
defects for more than 40 years (42). Several common modes of 
12                                                                                                                                                                                                                     Bone tissue engineering  
 
Regeneration, Reconstruction & Restoration 2016;1(1): 8-14 
  
Figure 5. The future of bone bioengineering 
 
electrical stimulation, such as pulsed electromagnetic field 
(PEMF), capacitive coupling (CC) and direct current (DC), 
have been used both experimentally and clinically to 
stimulate bone healing. Due to the piezoelectric properties of 
bone tissue, (43) rising the amount and speed of osteogenic 
differentiation by means of ES could be expected. Recent 
researches show that electrical stimulation can influence the 
expression of osteogenic marker genes in MSCs and greatly 
enhance alkaline phosphatase expression (44, 45). An in vivo 
study demonstrated that, electrical stimulation during 
mandibular lengthening accelerates the formation of new 
bone in rabbit model (46). Electrically stimulated periosteum 
grafting to a 12-year-old female patient who had a segmental 
mandibulectomy was successfully applied for mandibular 
reconstruction (47). These efforts suggest that electrical 
stimulation could be a promising tool for bone tissue 
engineering, particularly in the maxillofacial region.  
Bioreactors in bone tissue engineering 
Bioreactors are described as devices in which biological and 
biochemical processes are established under tightly controlled 
environment. Bioreactors enable the development of 3D tissues by 
providing biochemical (growth factors, proteins, etc.) and physical 
(e.g. oxygen level, mechanical stress, electrical stimulation, etc.) 
regulatory signals to cells and encouraging them to proliferate, 
differentiate and/or produce extracellular matrix (48). Originally, the 
goal behind developing most bioreactors was to test biomaterials by 
mimicking in vivo conditions; however, some of them were later 
invented with the goal of 3D ex vivo tissue development. Bioreactors 
have come a long way from simple cell culture dishes to complex co-
culture, perfusion, electro-/magnetic-/mechanical-stimulation 
systems. Recently developed bioreactor systems, invented to 
improve cell survival in scaled-up scaffolds (in terms of size and 
number), reach a new step of complexity in tissue engineering 
techniques (49). 
Bioreactors have been widely researched for bone tissue 
engineering applications. Particularly, the most important 
outcomes of the usage of bioreactors are enhanced mineralized 
matrix formation and osteoblastic differentiation (50). From a 
technical point of view, bioreactors can be classified into two 
main types: rotating wall vessels/spinner flasks and perfusion 
systems. These systems can be equipped with additional 
stimulation systems, which can provide magnetic, electrical 
and/or mechanical stimulations.  
In the context of bone tissue engineering, it is essential to 
note that bone tissue requires control of mechanical 
conditions. Spinner flask as a simple bioreactor system is 
designed to mix the culture medium by means of a stirrer, 
while scaffolds are secured from the top. Spinner flasks are 
often used in the culture of cells for bone tissue engineering. 
They have been shown to increase expression of osteoblastic 
markers in comparison with static culture and rotating vessel 
bioreactors. However, spinner flasks and rotating vessel 
bioreactors are not able to efficiently perfuse media into a 3D 
scaffold. Bioreactors, in which pump systems perfuse media 
directly through a scaffold, are known as perfusion bioreactors. 
These bioreactors not only circulate culture medium and 
control nutrition, pH and temperature conditions, but also 
Mobini & Ayoub                                                                                                                                                                                                         13 
    
Regeneration, Reconstruction & Restoration2016;1(1): 8-14 
cause the exposure of cells to fluid shear stress and provide 
mechanical stimulation, which is evidenced to be effective in 
osteogenic differentiation (51). Recently, presence of electric 
fields in bioreactors has attracted considerable attention. It has 
been shown that electrical fields have distinct effects on 
osteoblast lineage as they increase mineral formation (52). In 
this respect, the application of electrical fields in bioreactors 
seems to be a promising methodology in bone tissue 
engineering.  
Future outlook  
Tissue bioengineering is emerging to address a broad spectrum 
of clinical needs. However, it is still in its infancy. The 
sophistication and the range of human tissue that can be 
generated will increase dramatically in the future. There is a great 
deal of excitement in the clinical and academic circles to develop 
a reliable bone substitute with satisfactory mechanical properties 
for maxillofacial reconstruction capable to promote 
osteoinduction, osteoconduction and osteogenesis at the surgical 
site. Because of the pluripotency of stem cells they continue to be 
a major area of development.  Technical industrial advances, on 
the other hand, are underway to improve the quality of tissue 
engineered products and their safety. This multidisciplinary 
approach for bone bioengineering will have a significant impact 
on the quality of service delivered to patients (Figure 5). 
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